Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population.

Authors :: McHenry S
Park Y
Davidson NO
Source :: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2022 Nov; Vol. 20 (11), pp. 2638-2640. Date of Electronic Publication: 2021 May 25.
Publication Year :: 2022
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a global public health crisis that affects one quarter of the world population. <superscript>1</superscript> Preventing either cardiometabolic or liver-related complications by achieving weight loss and resolving hepatic steatosis would be the central goal of a NAFLD screening program in the primary care setting. Despite the overwhelming prevalence and the multimodal impact on health posed by NAFLD, specialty society guidelines do not recommend screening for NAFLD in the general population, <superscript>2</superscript> partly owing to the as-yet unproven cost benefit.<br /> (Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.)

Subjects :: Humans
Biological Specimen Banks
Weight Loss
Prevalence
United Kingdom epidemiology
Non-alcoholic Fatty Liver Disease diagnosis
Non-alcoholic Fatty Liver Disease epidemiology

Language :: English
ISSN :: 1542-7714
Volume :: 20
Issue :: 11
Database :: MEDLINE
Journal :: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Publication Type :: Academic Journal
Accession number :: 34044131
Full Text :: https://doi.org/10.1016/j.cgh.2021.05.035

Full Text Access

Tools